Surprise results of a temozolomide trial, and a new marker predicting who will benefit, offer hope for progress in the treatment of a highly aggressive brain tumour.
Related Articles
Impact Factor
Therapeutic options in recurrent glioblastoma – an update
Senza categoria
Newsround
Senza categoria